PDT Partners LLC Purchases 65,378 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)

PDT Partners LLC increased its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 30.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 280,382 shares of the company’s stock after acquiring an additional 65,378 shares during the period. PDT Partners LLC owned about 0.19% of Adaptive Biotechnologies worth $1,436,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Rubric Capital Management LP increased its position in Adaptive Biotechnologies by 2.9% in the third quarter. Rubric Capital Management LP now owns 14,400,000 shares of the company’s stock worth $73,728,000 after buying an additional 400,000 shares during the last quarter. Townsquare Capital LLC bought a new position in Adaptive Biotechnologies during the third quarter worth about $56,000. BNP Paribas Financial Markets increased its stake in shares of Adaptive Biotechnologies by 442.0% in the third quarter. BNP Paribas Financial Markets now owns 55,820 shares of the company’s stock worth $286,000 after purchasing an additional 45,521 shares in the last quarter. Millrace Asset Group Inc. bought a new stake in shares of Adaptive Biotechnologies in the third quarter valued at approximately $1,396,000. Finally, FMR LLC lifted its position in shares of Adaptive Biotechnologies by 102.0% during the third quarter. FMR LLC now owns 233,566 shares of the company’s stock worth $1,196,000 after acquiring an additional 117,965 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have commented on ADPT. BTIG Research raised their target price on Adaptive Biotechnologies from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, October 2nd. Piper Sandler boosted their price objective on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an “overweight” rating in a research note on Monday, November 11th.

Adaptive Biotechnologies Stock Performance

NASDAQ:ADPT opened at $5.94 on Monday. Adaptive Biotechnologies Co. has a 52-week low of $2.28 and a 52-week high of $6.70. The stock has a fifty day moving average of $5.07 and a 200 day moving average of $4.39. The firm has a market capitalization of $876.63 million, a price-to-earnings ratio of -4.43 and a beta of 1.45.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.